1. Performance comparison of two next-generation sequencing panels to detect actionable mutations in cell-free DNA in cancer patients
   Mónica Macías et al, 2020, Clinical Chemistry and Laboratory Medicine (CCLM) CrossRef
2. Lung cancer management: monitoring and treating resistance development in third-generation EGFR TKIs
   D. Franceschini et al, 2020, Expert Review of Anticancer Therapy CrossRef
3. The Diagnostic Accuracy of Liquid Biopsy in EGFR-Mutated NSCLC: A Systematic Review and Meta-Analysis of 40 Studies
   Naiqun Wang et al, 2021, SLAS Technology CrossRef
4. Predictive and Prognostic Markers for Cancer Medicine
   Elif Zeynep Yilmaz et al, 2020, Precision Medicine in Oncology CrossRef
5. Erlotinib versus gemcitabine/cisplatin in Chinese patients with EGFR mutation-positive advanced non-small-cell lung cancer: Crossover extension and post-hoc analysis of the ENSURE study
   Yi-Long Wu et al, 2019, Lung Cancer CrossRef
6. Concordance of Abundance for Mutational EGFR and Co-Mutational TP53 with Efficacy of EGFR-TKI Treatment in Metastatic Patients with Non-Small-Cell Lung Cancer
   Youping Wang et al, 2023, Current Oncology CrossRef
7. EGFR Mutation Analysis in Non-small Cell Lung Carcinoma Patients: A Liquid Biopsy Approach
   Jigna Joshi et al, 2021, Indian Journal of Clinical Biochemistry CrossRef
8. Real‐world analysis of the prognostic value of EGFR mutation detection in plasma ctDNA from patients with advanced non‐small cell lung cancer
   Chaolian Long et al, 2023, Cancer Medicine CrossRef
9. Detection of epidermal growth factor receptor mutations in peripheral blood circulating tumor DNA in patients with advanced non-small cell lung cancer
   Shunkai Zhou et al, 2020, Medicine CrossRef